A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Primary Objective

To compare efficacy between Arm A (sonrotoclax plus zanubrutinib [SZ]) versus Arm B (venetoclax plus obinutuzumab [VO]), as measured by progression-free survival (PFS) determined by the independent review committee (IRC).

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of MANALI KAMDAR

MANALI KAMDAR

Study ID

Protocol Number: 23-1756

More information available at ClinicalTrials.gov: NCT06073821

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers